Top ▲

ABCB subfamily C

Unless otherwise stated all data on this page refer to the human proteins. Gene information is provided for human (Hs), mouse (Mm) and rat (Rn).

Overview

Click here for help

« Hide

The ABCB subfamily is composed of four full transporters and two half transporters. This is the only human subfamily to have both half and full types of transporters. ABCB1 was discovered as a protein overexpressed in certain drug resistant tumor cells. It is expressed primarily in the blood brain barrier and liver and is thought to be involved in protecting cells from toxins. Cells that overexpress this protein exhibit multi-drug resistance [1,5].

Transporters

778
Click here for help

MDR1, PGP1 (ABCB1) C Show summary » More detailed page go icon to follow link

TAP1 (ABCB2) C Show summary »

TAP2 (ABCB3) C Show summary » More detailed page go icon to follow link

PGY3 (ABCB4) C Show summary »

ABCB5 C Show summary »

MTABC3 (ABCB6) C Show summary »

ABC7 (ABCB7) C Show summary »

MABC1 (ABCB8) C Show summary »

TAPL (ABCB9) C Show summary »

MTABC2 (ABCB10) C Show summary »

ABC16 (ABCB11) C Show summary »


Target Id 778
Systematic nomenclature ABCB11
Common abbreviation ABC16
Previous and unofficial names Bile salt export pump | BSEP | PFIC2 | PGY4 | SPGP | ABC16 | ABC member 16, MDR/TAP subfamily | progressive familial intrahepatic cholestasis 2 | ATP-binding cassette, sub-family B (MDR/TAP), member 11 | sister of P-glycoprotein | Lith1 | ATP-binding cassette, subfamily B (MDR/TAP), member 11 | ATP-binding cassette
Genes ABCB11 (Hs), Abcb11 (Mm), Abcb11 (Rn)
Ensembl ID ENSG00000073734 (Hs), ENSMUSG00000027048 (Mm), ENSRNOG00000050860 (Rn)
UniProtKB AC O95342 (Hs), Q9QY30 (Mm), O70127 (Rn)
Ligands
glycochenodeoxycholic acid (Binding) pKi 5.2 [3]
Comment Loss-of-function mutations are associated with progressive familial intrahepatic cholestasis type 2 [20]. ATP-dependent transport of bile acids into the confines of the canalicular space by ABCB11 (BSEP) generates an osmotic gradient and thereby, bile flow. Mutations in BSEP that decrease its function or expression cause Progressive Familial Cholestasis Type 2 (PFIC2), which in severe cases, can be fatal in the absence of a liver transplant. Drugs that inhibit BSEP function with IC50 values less than 25 μM [14] or decrease its expression [8] can cause Drug-Induced Liver Injury (DILI) in the form of cholestatic liver injury.

References

Click here for help

Show »

NC-IUPHAR subcommittee and family contributors

Show »

How to cite this family page

Database page citation (select format):

Concise Guide to PHARMACOLOGY citation:

Alexander SPH, Kelly E, Mathie A, Peters JA, Veale EL, Armstrong JF, Faccenda E, Harding SD, Pawson AJ, Sharman JL, Southan C, Davies JA; CGTP Collaborators. (2019) The Concise Guide to PHARMACOLOGY 2019/20: Transporters. Br J Pharmacol. 176 Issue S1: S397-S493.